Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 5/20 | 0.55 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SNCA | P37840 | 2/20 | 0.51 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358368 | 0.92 | MOGAT2 (0.61) | MOGAT2GSK3BMGAT2APPMAPT | |
| SCHEMBL5366407 | 0.90 | MOGAT2 (0.54) | MOGAT2GSK3BMGAT2APPMAPT | |
| SCHEMBL5370221 | 0.89 | MOGAT2 (0.57) | MOGAT2MGAT2APPMAPT | |
| SCHEMBL5361465 | 0.88 | MOGAT2 (0.59) | MOGAT2GSK3BMGAT2APPMAPT | |
| SCHEMBL5362785 | 0.88 | MOGAT2 (0.56) | MOGAT2MGAT2APPMAPT | |
| SCHEMBL5361301 | 0.88 | MOGAT2 (0.56) | MOGAT2GSK3BMGAT2 | |
| SCHEMBL5366196 | 0.88 | MOGAT2 (0.51) | MOGAT2GSK3BMGAT2NOX4 | |
| SCHEMBL5374131 | 0.88 | MOGAT2 (0.51) | MOGAT2GSK3BMGAT2NOX4 | |
| SCHEMBL5357745 | 0.88 | MOGAT2 (0.58) | MOGAT2GSK3BMGAT2 | |
| SCHEMBL5358480 | 0.87 | MOGAT2 (0.52) | MOGAT2GSK3BMGAT2MAPTNOX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| US-6506763-B2 | Useful in prevention and treatment of protein kinase related disorders such as cancer | SUGEN, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | MOGAT2 1159/4885GSK3B 315/4885MGAT2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.